Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Recent market launches and clearances include Glaukos’ iStent for glaucoma, Beckman Coulter’s Prostate Health Index blood test for prostate cancer and Siemens’ Sysmex CA-600 Systems for lab hemostasis testing.

You may also be interested in...

FDA Leaps To Draft Glaucoma Device Guidance

FDA issued a "leap frog" draft guidance for minimally invasive glaucoma surgery (MIGS) devices based on strong interest in the nascent field from manufacturers. The recommendations under the guidance reflect discussion during a 2014 stakeholder workshop.

PSA Prostate Cancer Screening Does More Harm Than Good, USPSTF Concludes

The final recommendations are a major shift in policy for the commonly performed blood test, and one certain to face ongoing controversy.

Glaukos Awaits iStent Approval, And New Randomized Trial Requirement

Glaukos will likely have to conduct a new, five-year prospective randomized post-market study for its iStent glaucoma device if FDA approves the product's PMA


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts